SCHEDULE: Vanguard Group Discloses 4.89% Stake in Pliant Therapeutics
Beneficial Ownership Report
The Vanguard Group has reported a 4.89% beneficial ownership stake in Pliant Therapeutics Inc., primarily holding sole dispositive power over its common stock.
Summary
- The Vanguard Group, an investment adviser based in Pennsylvania, has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Pliant Therapeutics Inc.
- As of June 30, 2025, Vanguard beneficially owns an aggregate of 3,002,348 shares of Pliant Therapeutics Inc. Common Stock.
- This aggregate amount represents 4.89% of the class of securities.
- Vanguard holds sole dispositive power over 2,982,841 shares and shared dispositive power over 19,507 shares.
- Vanguard reports no sole or shared voting power over these shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive. While a Schedule 13G is a factual report of ownership and not a direct endorsement, the disclosure of a significant stake by a major institutional investor like Vanguard is generally viewed favorably by the market as it indicates institutional interest and liquidity for the stock.
Positives
- The disclosure of a significant stake by a major institutional investor like The Vanguard Group can signal confidence in Pliant Therapeutics Inc.'s long-term prospects.
- Vanguard's passive investment approach, as indicated by the Schedule 13G filing, suggests a focus on long-term holding rather than activist intervention.
Negatives
- The filing itself does not contain any negative information regarding Pliant Therapeutics Inc.'s operations or financial performance.
Risks
- The filing does not detail specific risks related to Pliant Therapeutics Inc.'s business, as it is a disclosure of beneficial ownership by an institutional investor.
Future Outlook
The filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Pliant Therapeutics Inc.'s future performance or The Vanguard Group's investment strategy beyond the passive nature of the holding.
Industry Context
Pliant Therapeutics Inc. operates in the biotechnology or pharmaceutical sector, focusing on therapeutic developments. The Vanguard Group is one of the world's largest investment management companies, and its filings reflect broad market investment strategies, often through index funds or passively managed portfolios. This filing indicates Vanguard's routine investment in a publicly traded company within the healthcare industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by The Vanguard Group may enhance investor confidence and potentially improve liquidity for Pliant Therapeutics Inc.'s stock.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement (beneficial ownership reported as of this date). |
| 07/29/2025 | Date of signature for the Schedule 13G filing by The Vanguard Group. |
Keywords
Pliant Therapeutics Inc, Vanguard Group, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.